NCT06769217: EverGreen

Clinical Investigation for Everolimus Drug Eluting Stent

Completed Phase 4 Results posted Last updated 11 March 2026

What this trial tests

Phase 4 trial testing Drug Eluting Coronary Stent in Coronary Arterial Disease (CAD) in 888 participants. Completed in 30 January 2025.

Timeline

1 January 2023

Primary endpoint
8 November 2024

30 January 2025

Quick facts

Lead sponsor	Frisch Medical Device Private Limited
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	888
Start date	1 January 2023
Primary completion	8 November 2024
Estimated completion	30 January 2025
Sites	5 locations across Indonesia, India

Drugs / interventions tested

• Drug Eluting Coronary Stent

Conditions studied

• Coronary Arterial Disease (CAD) — all drugs for Coronary Arterial Disease (CAD) →

Sponsor

Frisch Medical Device Private Limited — full company profile →

Who can join

Adults 18 to 100, any sex, with Coronary Arterial Disease (CAD). Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days Primary · 30 days

The primary endpoint of the study is defined as Major Adverse Cardiac Events (MACE) at 30 days. Note: MACE rate is defined as the incidence of the combined clinical endpoint: Composite of Death (Cardiac death as well as Non-Cardiac), Myocardial Infarction (Q-wave and non-Q-wave), Emergency Coronary Artery Bypass Graft Surgery, clinically justified TLR within 30 days following index procedure.

Group	Value	95% CI
Single Arm	0

• MACE (%) Until 12 Months • Device-related SAEs Until 12 Months Secondary · 12 month

Angiographic success 100% Procedural success was demonstrated by restored TIMI grade 3 flow 97.07% Early device-related serious adverse events 0

Group	Value	95% CI
Single Arm	881

Sponsor's own description

History of Device Development and Study Rationale:

Drug-eluting stents (DES) revolutionized percutaneous coronary intervention (PCI) by significantly reducing restenosis and the need for repeat procedures compared to bare-metal stents (BMS). Introduced in the early 2000s, DES quickly became the standard of care due to its superior antiproliferative properties.

DES consists of a metal stent, an antiproliferative drug, and a polymer coating. The stent provides structural support while the drug is gradually released to inhibit tissue growth within the artery. This dual action effectively prevents restenosis, a common complication after PCI.

Contemporary guidelines strongly recommend DES over BMS for various clinical scenarios. The proven efficacy and safety of current-generation DES make them the preferred treatment option for patients undergoing PCI.

First-generation drug-eluting stents:

First-generation drug-eluting stents (DES) marked a significant advancement in interventional cardiology, addressing the persistent issue of in-stent restenosis (ISR) associated with bare-metal stents (BMS). These innovative devices, composed of a metal frame, an antiproliferative drug (sirolimus or paclitaxel), and a polymer coating, were designed to release the drug gradually, preventing tissue growth within the artery. Clinical trials demonstrated the superior efficacy of DES over BMS in reducing ISR and target lesion revascularization (TLR). The RAVEL trial, for example, found a dramatic decrease in ISR with sirolimus-eluting stents (SES). Subsequent studies and meta-analysis confirmed the benefits of both SES and paclitaxel-eluting stents (PES) compared to BMS, particularly in high-risk patients.

The introduction of DES represented a paradigm shift in interventional cardiology, offering a more effective and durable solution for patients with coronary artery disease.

Second-generation drug-eluting stents:

Second-generation drug-eluting stents (DES) were developed to address the safety concerns associated with first-generation DES, such as stent thrombosis (ST), incomplete endothelialization, and polymer-induced inflammation. These newer stents incorporate less toxic drugs, more biocompatible coatings, and thinner, more flexible struts. Clinical trials have demonstrated the superior safety and efficacy of second-generation DES compared to their predecessors. Studies comparing everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) to first-generation DES have shown significant reductions in ST, myocardial infarction (MI), and target lesion revascularisation (TLR). Head-to-head comparisons of EES and ZES have also revealed comparable outcomes in real-world patient populations. Both stents are effective and safe for the treatment of obstructive coronary artery disease, making them the preferred choice for percutaneous coronary intervention.

Study Rationale:

The introduction of drug-eluting stents (DES) marked a significant leap in interventional cardiology by addressing the limitations of bare-metal stents (BMS), primarily through reducing restenosis and the need for repeat procedures. First-generation DES, equipped with antiproliferative drugs like sirolimus and paclitaxel, demonstrated superior efficacy in preventing in-stent restenosis. However, safety concerns, including stent thrombosis and polymer-induced inflammation, led to the development of second-generation DES, which utilizes more biocompatible materials and refined designs. Clinical trials have consistently shown that these newer DES offer enhanced safety and effectiveness, solidifying their position as the preferred treatment option in percutaneous coronary interventions.

Study Objectives

The main objective of this study is to assess the safety and effectiveness of the EvroSure Everolimus Drug eluting CoCr stent in obstructive coronary artery disease.

Primary Objective

The primary endpoint of this study is to monitor Major Adverse Cardiac Events (MACE) at 30 days.

Secondary Objective

The following secondary effectiveness endpoints are as follows:

* Angiographic/device success (%)
* Procedural success (%)
* Clinically justified Target Lesion Revascularization (TLR) (%) at 12 months

The following secondary safety endpoints are:

* MACE (%) until 12 months (Clinically Justified)
* Device-related SAEs until 12 months (Clinically Justified)

Note: MACE rate is defined as the incidence of the combined clinical endpoint: Composite of Death (Cardiac death as well as Non-Cardiac), Myocardial Infarction (Q-wave and non-Q-wave), Emergency Coronary Artery Bypass Graft Surgery, clinically justified TLR following index procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.